(Q34649075)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23555026%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

title

The Akt inhibitor ISC-4 synergizes with cetuximab in 5-FU-resistant colon cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23555026%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23555026%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Arun K Sharma

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23555026%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Wafik El-Deiry

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23555026%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

author name string

Joshua E Allen

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23555026%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

David T Dicker

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23555026%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Shantu Amin

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23555026%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Rosalyn B Irby

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23555026%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

language of work or name

English

0 references

publication date

12 March 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23555026%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23555026%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23555026%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23555026%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

page(s)

e59380

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23555026%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

27 February 2020

copyright license

start time

12 March 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595267

7 July 2018

Cancer statistics, 2012

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595267

The Akt inhibitor ISC-4 activates prostate apoptosis response protein-4 and reduces colon tumor growth in a nude mouse model.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595267

Melanoma chemoprevention in skin reconstructs and mouse xenografts using isoselenocyanate-4.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595267

Circulating Tumor Cells and Colorectal Cancer.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595267

Targeting Akt3 signaling in malignant melanoma using isoselenocyanates

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595267

Synthesis and anticancer activity comparison of phenylalkyl isoselenocyanates with corresponding naturally occurring and synthetic isothiocyanates.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595267

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595267

Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595267

Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595267

Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595267

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595267

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595267

Chemoprevention by isothiocyanates and their underlying molecular signaling mechanisms

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595267

Cancer-preventive isothiocyanates: measurement of human exposure and mechanism of action.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595267

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595267

Disruption of p53 in human cancer cells alters the responses to therapeutic agents

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595267

Identifying circulating tumor stem cells that matter: the key to prognostication and therapeutic targeting

7 July 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23555026

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1371/JOURNAL.PONE.0059380

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23555026%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23555026%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23555026%20AND%20SRC:MED&resulttype=core&format=json